

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|--|-----------------------------|---|---|
| | | 4550081 | 10-29-1985 | Stocker | |
| | | 4530901 | 7-23-1985 | Weissman | |
| | | 4440859 | 04-09-1984 | Rutter | |
| | | 4582800 | 04-15-1986 | Crowl | |
| | | 4677063 | 06-30-1987 | Mark | |
| | | 4704362 | 11-03-1987 | Itakura | |
| | | 4710463 | 12-01-1987 | Murray | |
| | | 4766075 | 09-23-1988 | Goeddel | |
| | | 4757006 | 07-12-1988 | Toole | |
| | | 4810648 | 03-07-1989 | Stalker | |
| | | 4837151 | 06-06-1989 | Stocker | |
| | | 5356797 | 10-18-1994 | Nielsen | |
| | | 5397697 | 03-14-1995 | Lam | |
| | | 5210035 | 5-11-1993 | Stocker | |
| | | 5643579 | 07-01-1997 | Hung | |
| | | 6251406 | 06-26-2001 | Haeffliger | |
| | | 6458368 | 10-01-2002 | Haeffliger | |
| | | 6585975 | 01-07-2003 | Kleanthous | |
| | | 6756042 | 6-29-2004 | Feldman | |
| | | 6846667 | 01-25-2005 | Crooke | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 2 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|--|-----------------------------|---|---|
| | | 6936425 | 08-30-2005 | Hensel | |
| | | 6951732 | 10-04-2005 | Clarke | |
| | | 6984490 | 01-10-2006 | Holden | |
| | | 7211264 | 05-01-2007 | Feldman | |
| | | 7449178 | 11-11-2008 | Crooke | |
| | | 20040203039 | 10-14-2004 | Hensel | |
| | | 20060216309 | 09-28-2006 | Holden | |
| | | 20080075739 | 03-27-2008 | Hensel et al. | |
| | | 20080175866 | 07-24-2008 | Holdon | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---|-----------------------------|---|---|----------------|
| | | WO 9220805 | 11-26-1992 | PF Medicament | | |
| | | WO 9310246 | 05-27-1993 | University of Texas | | |
| | | WO 9411024 | 05-26-1994 | Univ. Minnesota | | |
| | | WO 9611708 | 04-25-1996 | University of Texas | | |
| | | WO 9718225 | 05-22-1997 | Gen. Hospital Corp. | | |
| | | WO 9806428 | 02-19-1998 | UAB Research Foundation | | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 3 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁵ (if known) | Publication Date MM-DD- YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|---|---------------------------------------|--|--|----------------|
| | | WO 9835562 | 08-20-1998 | Merck & Co Inc. | | |
| | | EP 0889120 | 01-07-1999 | Imp College Innovations | | |
| | | WO 9945120 | 09-01-1999 | Biotech&Biolog Scien Res | | |
| | | WO 9901473 | 01-14-1999 | Imp College Innovations | | |
| | | WO 0014240 | 03-16-2000 | Creatogen Biosciences | | |
| | | WO 03044047 | 05-30-2003 | London School of Hygiene | | |
| | | WO 0132697 | 05-10-2001 | Unite de Rech en Biol Molecu | | |
| | | WO 0185772 | 11-15-2001 | Microscience Ltd. | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | ABAEV, et al. (1997) "Stable expresion of heterologous proteins in Salmonella: Problems and approaches to their designing," Vestn. Ross Akad Med Nauk 6:48-52 ABSTRACT ONLY | No |
| | | AGRAWAL and GOODCHILD (1987) "Oligodeoxynucleotide methylphosphonate: synthesis and enzymatic degradation." Tetrahedron Letters, 28:3536-3542 | |
| | | AGRAWAL and TANG (1990) "Efficient synthesis of oligoribonucleotide and its phosphorothioate analogue using H-Phosphonate Approach," Tetradhedron Letters, 31:7541-7544 | |
| | | AGRAWAL (1998) "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," PNAS 85:7079-7083 | |
| | | AGRAWAL (1990) "Site-specific excision from RNA by RNase H and mixed phosphate-backbone oligodeoxyribonucleotides." PNAS 87:1401-1405 | |
| | | AGRAWAL et al. (1991) "Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice," PNAS, 88:7595-7599 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | ALLAOUI, et al. (1993) "MxiD, an outer membrane protein necessary for the secretion of Shigella flexneri lpa invasins," Mol. Microbiol., 7:59-68 | |
| | | ALTMAYER, et al. (1993) "Cloning and molecular characterization of gene involved in Salmonella adherence and invasion of cultured epithelial cells," Mol. Microbiol., 7:89-98. | |
| | | ANDREWS and MAURELLI (1992) "MxiA of Shigella flexneria 2a, which facilitates export of invasion plasmid antigens encodes a homol of low-calcium-response protein LcrD, of Yersinia pestis," Infect. Immun. 60:3287-3295 | |
| | | BACHMAN (1990) "Linkage map of E. coli K-12," Micro. Rev. 54:130-197. | |
| | | "BAJAJ, et al. (1996) "Co-ordinate regulation of Salmonella typhimurium invasion genes by environmental and regulatory factor is mediated by control of expression," Mol. Microbiol. 18:715-727 | |
| | | BAJAJ, et al. (1995) "'hilA is notvel ompR/toxR family member that activates the expression of Salmonella typhimurium invasion genes." Mol. Microbiol. 18:715-727. | |
| | | BANNWARTH (1988) "Solid-phase synthesis of oligodeoxynucleotides containing phosphoramidate internucleotide linkages and their specific chemical cleavage," Helv. Chim. Acta. 71:1517-1527 | |
| | | BAUDRY, et al. (1988) "Nucleotide sequence of the invasion plasmid antigen B and C genes (ipaB and ipaC) of Shigella flexneri," Microb. Pathog. 4:345-357 | |
| | | BENSON and GOLDMAN (1992) "Rapid mapping in Salmonella typhimurium with Mud-P22 prophages," J. Bacteriol. 175:1673-1681 | |
| | | BODDIKCE, et al. (2006) "Signature-tagged mutagenesis of Klebsiella pneumoniae to identify genes that influence biofilm formation on extracellular matrix material," Infect. Immun. 74:4590-4597 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|--|----------------|
| | | BOGDANOVE, et al. (1996) "Unified nomenclature for broadly conserved hrp genes of phytopathogenic bacteria," Mol. Microbiol. 20:681-683 | |
| | | BOURGOGNE, et al. (1998) "Salmonella abortusovus strain RV6, new vaccinal vehicle for small ruminants," Vet. Microbiol. 61:199-213 ABSTRACT ONLY | |
| | | CARDENAS, et al. (1994) "Influence of strain viability and antigen done on the use of attenuated mutants of Salmonella as vaccine carriers," Vaccine 12:883-840 | |
| | | CARDENAS, et al. (1993) "Stability, immunogenicity and expression of foreign antigens in bacterial vaccine vectors," Vaccine 11:122-125 ABSTRACT ONLY | |
| | | CARDENAS, et al. (1992) "Oral administration using live attenuated Salmonella spp. as carriers of foreign antigens," Clin. Microbiol. Rev. 5:328-342 | |
| | | CATTOZZO, et al. (1997) "Expression of immunogenicity of V3 loop epitopes of HIV isolates SC and WMJ2, inserted in Salmonella flagellin," J. Biotechnol. 56:191-203 ABSTRACT ONLY | |
| | | CHABALGOITY, et al. (1996) "A Salmonella typhimurium htrA live vaccine expressing multiple copies of a peptide comprising amino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanus toxin fragment C protects mice from herpes simplex virus infection," Mol. Microbiol. 19:791-801 | |
| | | CHACON, et al. (1996) "Heterologous expression of the citric glutathione peroxidase of lymphatic filariae in an attenuated vaccine strain of Salmonella typhimurium abrogates H-2 restriction of specific antibody response," Parasite Immunol. 18:307-316 ABSTRACT ONLY | |
| | | CHANG, et al. (1978) "Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid" J. Bacteriol. 134:1141-1156 | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | CHARLES, et al. (1990) "Gene expression an the development of live enteric vaccines," Trends Biotechnol. 8:117-121 ABSTRACT ONLY | |
| | | CHATFIELD, et al (1992) "Construction of a genetically defined Salmonella typhi Ty2 aro A, aroC mutain for the engineering of a candidate oral typhoid-tetanus vaccine," Vaccine 10:53-60 | |
| | | CHATFIELD, et al. (1994) "The use of live attenuated Salmonella for oral vaccination," Dev. Biol. Stand. 82:35-42 | |
| | | CHATFIELD, et al. (1993) "The development of oral vaccines based on live attenuated <i>Salmonella</i> strains," FEMS Immunol. Med. Microbiol. 7:1-7 | |
| | | CHATFIELD, et al. (1995) "The development of oral vaccines against parasitic diseases utilizing live attenuated <i>Salmonella</i> ," Paristology 110Suppl.:S17-S24 | |
| | | CHATFIELD, et al. (1989) "Live Salmonella vaccines and carriers of foreign antigenic determinants," Vaccine 7:495-498 | |
| | | CIRILLO, et al. (1995) "Bacterial vaccine vectors and bacillus Calmette-Guerin," Clin. Infect. Dis. 30:1001-1009. | |
| | | CLEMENS (1987) "Use of attenuated mutants of Salmonella as carriers for delivery of heterologous antigens to the secretory immune system," Pathol. Immunopathol. Res. 6:137-146 | |
| | | CLEMENTS (1990) "Vaccines against enterotoxigenic bacterial pathogens based on hybrid Salmonella that express heterologous antigens," Res. Microbiol. 141:981-993. ABSTRACT ONLY | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | COHEN, et al. (1990) "Microbial isopenicillin N synthase genes: structure, function, diversity and evolution," Trends in Biotechnol. 8:105-111 | |
| | | COLLAZO, et al. (1995) "Functional analysis of the Salmonella typhimurium invasion genes invI and invJ and identification of a target of the protein secretion apparatus encoded in the inv. locus," Mol. Microbiol. 15:25-38 | |
| | | COSSTICK and VYLE (1989) "Solid phase synthesis of oligonucleotides containing 3'-thioymidase," Tetrahedron Letters, 30:4693:4696 | |
| | | COVONE, et al. (1998) "Levels of expression and immunogenicity of attenuated Salmonella enterica serovar typhimurium strains expression Escherichia coli mutant heat-labile enterotoxin," Infect. Immun. 66:224-231 | |
| | | COYNAULT, et al. (1992) "Growth phase and SpvR regulation of transcription in Salmonella typhimurium spvANC virulence genes," Microb. Pathog. 13:133-143. ABSTRACT ONLY | |
| | | CURTISS, et al. (1990) "Stabilization of recombinant avirulent vaccine strains in vivo," Res. Microbiol. 141:797-805. ABSTRACT ONLY | |
| | | DAVIDSON, et al. (1995) "Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens," Nat. Genet. 9:351-357 | |
| | | DE LORENZO, et al. (1990) "Mino-Tn5 transposon derivatives for insertion mutagenesis promoter probing, and chromosomal insertion of cloned DNA in gram-negative eubacteria," J. Bacteriol. 172:6568-6572 | |
| | | DE LORENZO and TIMIS (1994) "Analysis of stable phenotypes in gram negative bacteria with Tn5 and Tn10-derived minitransposons," Methods Enzymol. 235:386-405 | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | DEGROOTE, et al (1997) "Periplasmic superoxide dismutase protects Salmonella from products of phagocyte NADPH-oxidase and nitric oxide synthase," PNAS 94:13997-14001 | |
| | | DEIWEICK, et al. (1999) "Environmental regulation of Salmonella pathogenicity island 2 gene expression," Mol. Microbiol. 31:1759-1773 | |
| | | DIEDERICH, et at. (2000) "In search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs): Chenodeoxycholic acid selectivity inhibits 11beta-HSD-1" Eur. J. Endocrinol. 142:200-207 | |
| | | DEIWICK and HENSEL (1999) "Regulation of virulence genes by environmental signal in Salmonella typhimurium electrophoresis," 20:813-817. ABSTRACT ONLY | |
| | | DOGGETT, et al. (1993) "Immune response to Streptococcus sobrinus surface protein antigen A expressed by recombinant Salmonella typhimurium," Infect. Immun. 61:1859-1866 | |
| | | DONNENBERG, et al. (1991) "Construction of an eae deletion mutant of enteropathogenic Escherichia coli using a positive-selection suicide vector," Infect. Immunol. 59:4310-4317 | |
| | | DOUGAN, et al. (1989) "Live bacterial vaccines and their application as carrier for foreign antigen," Adv. in Vet. Sci. and Comp. Med. 33:277-300 | |
| | | DOUGAN, et al. (1987) "Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system," Parasite Immunol. 9:151-160 | |
| | | EICHELBERG, et al. (1994) "Molecular and functional characterization of the Salmonella typhimurium invasion genes invB and invC: homology of invC to the FOF1 ATPase family of proteins," J. Bacteriol. 176:4501-4510 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | ELLIOT, et al. (1998) "The complete sequence of the locus of enterocyte affacement (LEE) from enteropathogenic Escherichia coli E2348/49," Mol. Microbiol. 28:1-4 | |
| | | EVERST, et al. (1995) "Expression of LacZ from the hrtA, nirB and groE promoters in a Salmonella vaccine strain: influence of growth in mammalian cells," FEMS Microbiol. Letters 126:97-101 | |
| | | FAYOLE, et al. (1994) "Genetic control of antibody responses induced against an antigen delivered by recombinant attenuated Salmonella typhimurium," Infect. Immun. 62:4310-4319 | |
| | | FIELDS, et al. (1986) "Mutants of Salmonella typhimurium that cannot survive within the macrophage are invirulent," PNAS 83:5189-5193 | |
| | | FIERER, et al. (1993) "Expression of the Salmonella virulence plasmid gene spvB in cultured macrophages and nonphagocytic cells," Infect. Immun. 61:5231-5236 | |
| | | FINLAY, et al. (1991) "Cytoskeletal rearrangements accompanying Salmonella entry into epithelial cells," 99:283-296 | |
| | | FINLAY (1994) "Molecular and cellular mechanisms of Salmonella pathogenesis" Curr. Top. Microbiol. Immunol. 192:163-185 | |
| | | FOULONGNE, et al. (2000) "Identification of Brucella suis genes affecting intracellular survival in an in vitro human macrophage infection model by signature-tagged transposon mutagenesis," Infect. Immun. 68:1297-1303 | |
| | | FORSBERG, et al. (1994) "Use of transcriptional fusions to monitor gene expression: a cautionary tale," J. Bacteriol. 176:2128-2132 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | FOUTS, et al. (1995) "Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120," Vaccine 13:1697-1705. ABSTRACT ONLY | |
| | | FOUTS, et al. (1995) "Construction and characterization of Salmonella-typhi based human immunodeficiency virus type 1 vector vaccine," Vaccine 13:561-569. ABSTRACT ONLY | |
| | | FRANCIS et al. (1992) Morphological and cytoskeletal changes in epithelial cells occur immediately upon interaction with Salmonella typhimurium grown under low-oxygen conditions," Mol. Microbiol. 6:3077-3087 | |
| | | GENTSCHEV, et al. (1998) "Delivery of the p67 sporozite antigen Theileria parva by using recombinant Salmonella dublin: secretion of the product enhances specific antibody responses in cattle," Infect. Immun. 66:2060-2064 | |
| | | GINNOCHIO, et al. (1992) "Identification and molecular characterization of a Salmonella typhimurium gene involved in triggering the internalization of Salmonella into cultured epithelial cells," PNAS 89:1575-5980 | |
| | | GINNOCCHIO, et al. (1994) "Contact with epithelial cells induces the formation of surface appendages on Salmonella typhimurium," Cell 76:717-724 | |
| | | GUILLOBEL, et al. (1998) "Immunization against the colonization factor antigen I of enterotoxigenic Escherichia coli by administration of a bivalent Salmonella typhimurium aroA strain," Braz. J. Med. Biol. Res. 31:545-554. ABSTRACT ONLY | |
| | | GUNN and MILLER (1996) "PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance," J. Bacteriol. 178:6857-6864 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|--|----------------|
| | | GUY, et al. (2000) "Aggregation of host endosomes by Salmonella requires SPI2 translocation of SseGF and involves SpvR and the fms-aroE intergenic region," Mol. Microbiol. 37:1417-1435. ABSTRACT ONLY | |
| | | HADDAD, et al. (1995) "Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity," FEMS Immunol. Med. Microbiol. 12:175-186. ABSTRACT ONLY | |
| | | HAHN, et al. (1998) A Salmonella typhimurium strain genetically engineered to secrete a bioactive human interleukin (hIL)-6 via the Escherichia coli hemolysin secretion apparatus," FEMS Immunol. Med. Microbiol. 20:111-119. ABSTRACT ONLY | |
| | | HAKANSSON, et al. (1996) "The YoB protein of Yersinia pseudotuberculosis is essential for the translocation of Yop effector proteins across the target cell plasma membrane and displays a contact-dependent membrane disrupting activity," EMBO J. 15:5812-5823 | |
| | | HAROKOPAKIS et al. (1997) "Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of co-expressed cholera toxin A2 and B subunits," Infect. Immun. 65:1445-1454 | |
| | | HAUSER, et al. (1998) "Defects in type III secretion correlate with internalization of Pseudomonas aeruginosa by epithelial cells," Infect. Immun. 66:1413-1420 | |
| | | HAVAARSTEIN, et al. (1995) "An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae," PNAS 92:11140-11144 | |
| | | HE, et al. (2000) "Function of human brain short chain L-3 hydroxyl coenzyme A dehydrogenase in androgen metabolism," Biochemica Et. Biophysica Acta:1484:267-277 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | HEITHOFF, et al. (1999) "An essential role for DNA adenine methylation in bacterial virulence," Science 284:967-970 | |
| | | HENSEL and HOLDEN (1996) "Molecular genetic approaches for the study of virulence in both pathogenic bacteria and fungi," Microbiol. 142:1049-1058 | |
| | | HERRERO, et al. (1990) "Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in gram negative bacteria," J. Bacteriol. 172:6557-6567 | |
| | | HESS, et al. (1997) "Protection against murine listeriosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the naturally somatic antigen superoxide dismutase," Infect. Immun. 65:1286-1292 | |
| | | HESS, et al. (1995) "Listeria monocytogenes p60 supports host cell invasion by and in vivo survival of attenuated Salmonella typhimurium," Infect. Immun. 63:2047-2053 | |
| | | HESS, et al. (1996) "Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis," PNAS 93:1458-1463 | |
| | | HESS, et al. (1997) "Modulation of antigen display by attenuated Salmonella typhimurium strains and its impact on protective immunity against listeriosis," Behring Inst. Mitt. 160-171 | |
| | | HIRAKATA, et al. (1992) "Efficacy of erythromycin lactobionate for treating Pseudomonas aeruginosa bacteremia in mice," Antimicrob. Agents Chemother. 36:1198-1203 | |
| | | HOFFMAN and STOFFEL (1993) "TMbase-a database of membrane spanning protein segments," Biol. Chem. Hoppe-Seyler 347:166 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|--|----------------|
| | | HOHMANN, et al. (1995) "Macrophage-inducible expression of a model antigen in Salmonella typhimurium enhances immunogenicity," PNAS 92:2904-2908 | |
| | | HOHMANN, et al. (1996) "Evaluation of phoP/phoQ-deleted aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers," Vaccine 14:19-24 | |
| | | HOLDEN, et al. (1989) "Mutation in heat-regulated hsp70 gene of Ustilago maydis," EMBO J. 8:1927-1934 | |
| | | HOLTEL, et al. (1992) "Upstream binding sequences of the XylR activator protein and integration host factor in the xylS gene promoter region of the Pseudomonas TOL plasmid," Nucl. Acid Res. 20:1755-1762 | |
| | | HONE, et al. (1988) "A chromosomal integration system for stabilization of heterologous genes in Salmonella based vaccine strains," Microb. Pathog. 5:407-418. ABSTRACT ONLY | |
| | | HORMAECHE, et al. (1996) "Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)-dependent and only partially determined by the main LPS O antigen," Vaccine 14:251-259. ABSTRACT ONLY | |
| | | HORMAECHE, et al. (1991) "Live attenuated Salmonella vaccines and their potential as oral combined vaccines carrying heterologous antigens," J. Immunol. 142:113-120. ABSTRACT ONLY | |
| | | HUECK (1998) "Type III protein secretion systems in bacterial pathogens of animals and plants," Microbiol. Mol. Biol. Rev. 62:379-433 | |
| | | HUECK, et al. (1995) "Salmonella typhimurium secreted invasion determinants are homologous to Shigella lpa proteins," Mol. Microbiol. 18:479-490 | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | JAGER, et al. (1988) "Oligonucleotide N-alkylphosphoramidates: synthesis and binding to polynucleotides," Biochemistry 20:7237-7246 | |
| | | JANSSEN, et al. (1995) "Induction of the phoE promoter upon invasion of Salmonella typhimurium into eukaryotic cells," Microb. Pathog. 19:193-201. ABSTRACT ONLY | |
| | | JORNVALL, et al. (1995) "Short chain dehydrogenases/reductases (SDR)" Biochemistry 34:6003-6013 | |
| | | JORNVALL, et al. (1999) "SDR and MDR: Completed genome sequences show these protein families to be large, of old origin and complex nature," FEBS Letters 445:261-264 | |
| | | KANIGA, et al. (1995) "Homologs of the Shigella lpa and lpc invasins are required for Salmonella typhimurium entry into cultured epithelial cells," J. Bacteriol. 177:3965-3971 | |
| | | KANIGA, et al. (1994) "The Salmonella typhimurium invasion genes invF and invG encode homologs of the AraC and PulD family of proteins," Mol. Microbiol. 13L555-568 | |
| | | KAREM, et al. (1996) "Cytokine expression in the gut associated lymphoid tissue after oral administration of attenuated Salmonella vaccine strains," Vaccine 14:1495-1502. ABSTRACT ONLY | |
| | | KIRSCH and DI DOMENICO (1993) "The discovery of natural products with a therapeutic potential," V.P. Gallo, Ed. Chapter 6, pages 1770221, Butterworth, V.K. | |
| | | KRUL, et al. (1996) "Induction of an antibody response in mice against human papilloma virus (HPV) type 16 after immunization with HPV recombinant Salmonella strains," Cancer Immunol. 43:44-48 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | KUWAJIA, et al. (1989) "Export of N-terminal fragment of Escherichia coli flagellin by a flagellum-specific pathway," PNAS, 86:4953-4957 | |
| | | LAEMMLI (1970) "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," Nature 227:680-685 | |
| | | LEARY, et al. (1997) "Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague," Microb. Pathog. 23:167-179. ABSTRACT ONLY | |
| | | LEE, et al. (1992) "Identification of a Salmonella typhimurium invasion locus by selection for hyperinvasive mutants," PNAS 89:1847-1851 | |
| | | LEITER, et al. (1990) "Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides," PNAS 87:3430-3434 | |
| | | LENZ, et al. (2000) "Chemical ligands, genomics and drug delivery," Drug Discovery Today 5:145-156 | |
| | | LEVINE, et al. (1996) "Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors." J. Biotechnol. 44(1-3):193-196 | |
| | | LILJEVIST, et al. (1996) "A novel expression system for Salmonella typhimurium, allowing high production levels, product secretion and efficient recovery," Biochem. Biophys. Res. Com. 218:356-359. ABSTRACT ONLY | |
| | | LINGBERG (1995) "The history of live bacterial vaccines," Dev. Biol. Stand. 84:211-219. ABSTRACT ONLY | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | LI, et al. (1995) "Relationship between evolutionary rate and cellular location among the Inv/Spa invasion proteins of Salmonella enterica," PNAS 92:7252-7256 | |
| | | LO-MAN, et al. (1996) "Control by H-2 genes of the Th1 response induced against foreign antigen expressed by attenuated Salmonella typhimurium," Infect. Immun. 64:4424-4432 | |
| | | LOWE, et al. (1999) "Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC and htrA" Infect. Imm. 67:700-707 | |
| | | MACNAB (1996) "Flagella and motility in Escherichia coli and Salmonella: cellular and molecular biology," F.C. Neidardt, et al. (eds.) Washington, D.C.:ASM Press: 123-145 | |
| | | MASKELL, et al. (1987) "Salmonella typhimurium aroA mutants as carriers of Escherichia coli heat labile enterotoxin B subunit to the murine secretory and systemic immune systems," Microb. Pathog. 2:2211-221. ABSTRACT ONLY | |
| | | MAURER, et al. (1984) "Functional interchangeability of DNA replication genes in Salmonella typhimurium and Escherichia coli demonstrated by a general complementation procedure," Genetics 108:1-23 | |
| | | MCSORLEY, et al. (1997) "Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters," Infect. Immun. 65:171-178 | |
| | | MICHIELS, et al. (1991) "Analysis of virC, an operon involved in the secretion of Ypo proteins by Yersinia enterocolitica," J. Bacteriol. 173:4994-5009 | |
| | | MILICH, et al. (1995) "The hepatitis nucleocapsid as a vaccine carrier moiety," Ann. NY Acad. Sci. 754:187-201. ABSTRACT ONLY | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | MILLER and MEKALANOS (1998) "A novel suicide vector and its use in construction of inversion mutations: osmoregulation of outer membrane proteins and virulence determinants in <i>Vibrio cholerae</i> requires ToxR," J Bacteriol. 170:2575-2593 | |
| | | MILLER et al. (1993) "The PhoP virulence regulon and live oral <i>Salmonella</i> vaccines," Vaccine 11:122-125 | |
| | | MINAMINO, et al (1999) "Components of the <i>Salmonella</i> flagellar export apparatus and classification of export substrates," J. Bacteriol. 181:1388-1394 | |
| | | MIRAS, et al. (1995) "Nucleotide sequence of <i>iagA</i> and <i>iagB</i> genes involved in invasion of HeLa cells by <i>Salmonella enterica</i> subsp. <i>Enterica</i> Ser. Typhi" Res. Microbiol. 146:17-20 | |
| | | MONACK, et al. (1996) "Salmonella typhimurium invasion induces apoptosis in infected macrophages," PNAS 93:9833-9838 | |
| | | NEWTON, et al. (1995) "Studies of the anaerobically induced promoter <i>pnrB</i> and the improved expression of bacterial antigens" 146:193-202 | |
| | | NIELSON, et al. (1998) "Synthesis and characterization of dinucleoside phosphorodithioates," Tetrahedron Letters, 29:2911-2914 | |
| | | OCALLAGHAN and CHARBIT (1990) "High efficiency transformation of <i>Salmonella typhimurium</i> and <i>Salmonella typhi</i> by electroporation," Mol. Gen. Genet. 223:156-158 | |
| | | OBEYSEKERE et al (1998) "Serines at the active site of 11 beta-hydroxysteroid dehydrogenase type I determine the rate of catalysis" Biochem. Biophys. Res. Commun. 250:469-473 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|--|----------------|
| | | OHARA, et al. (1989) "Direct genomic sequencing of bacterial DNA: the pyruvate kinase I gene of Escherichia coli," PNAS 86:6883-6887 | |
| | | OKAHASHI, et al. (1996) "Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonell strain or cholera toxin reveals CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses," Infect. Immun. 64:1516-1525 | |
| | | OPPERMAN, et al. (1997) "Structure function relationships of SDR hydroxysteroid dehydrogenases," Advances in Exp. Med. and Biol. 414:403-415 | |
| | | ORR, et al. (1999) "Expression and immunogenicity of a mutant diphtheria toxin molecule, CRM197, and its fragments in Salmonella typhi vaccine strain CVD 908-htrA" Infect. Immun. 67:4290-4294 | |
| | | PALLEN, et al. (1997) "Coiled-coil domains in proteins secreted by type III secretion systems," Mol. Microbiol. 25:423-425 | |
| | | PEARCE, et al (1993) "Genetic identification of exported proteins in Streptococcus pneumoniae," Mol. Microbiol. 9:1037-1050 | |
| | | PERLMAN and FREEDMAN (1971) "Experimental endocarditis. II Staphylococcal infection of the aortic valve following placement of polyethylene catheter in the left side of the heart." Yale J. Biol. Med. 44:203-213 | |
| | | PLANO, et al. (1991) "LcrD, a membrane-bound reegulator of the Yersinia pestis low-calcium response," J. Bacteriol. 173:7293-7303 | |
| | | POZZA, et al.. (1998) "Construction and characterization of Salmonella typhimurium aroA simultaneously expressing the five pertussis toxin subunits," Vaccine 16:522-529. ABSTRACT ONLY | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 19 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | RALPH, et al. (1975) "Reticulum cell sarcoma: and effector cell in antibody-dependent cell-mediated immunity," J. Immunol. 114:898-905 | |
| | | REED and MUENCH (1938) "A simple method of estimating fifty per cent end points," Am J. Hyg. 27:493-497 | |
| | | RHEN, et al. (1993) "Transcriptional regulation of Salmonella enterica virulence plasmid genes in cultured macrophages," Mol. Microbiol. 10:45-56. ABSTRACT ONLY | |
| | | RONSON, et al. (1987) "Conserved domains in bacterial regulatory proteins that respond to environmental stimuli," Cell 49:579-581 | |
| | | ROY and COLEMAN (1994) "Mutations in firA, encoding the second acyltransferase in lipopolysaccharide biosynthesis, affect multiple steps in lipopolysaccharide biosynthesis," 176:1639-1646 | |
| | | SAIKI et al. (1988) "Primer directed enzymatic amplification of DNA with a thermostable DNA polymerase," Science 242:1503-1506 | |
| | | SALMOND and REEVES (1993) "Membrane traffic wardens and protein secretion in gram negative bacteria," Trends in Biochem. Sci. 18:7-12 | |
| | | SANDERSON, et al. (1995) "Genetic map of Salmonella typhimurium, edition VIII," Microbiol. Rev. 59:241-303 | |
| | | SANGER, et al. (1977) "DNA sequence with chain terminating inhibitors," PNAS 74:5463-5467 | |

| | | | |
|--|--|------------------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | SARIN, et al. (1988) "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," PNAS 85:7448-7451 | |
| | | SASAKAWA, et al. (1993) "Eight genes in region 5 that form an operon are essential for invasion of epithelial cells by Shigella flexneria 2a," J. Bacteriol. 175:2334-2346 | |
| | | SCHMITT et al. (1996) "The attenuated phenotype of a Salmonella typhimurium flgM mutant is related to expression of FlhC flagellin," J. Bacteriol. 178:2911-2915 | |
| | | SCHODEL, et al. (1990) "Hepatitis B Virus Nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination" J. Immunol. 145:4317-4321 | |
| | | SCHODEL (1990) "Oral vaccination using recombinant bacteria," Semin. Immunol. 12:341-349 | |
| | | SHAW et al. (1991) "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," Nucleic Acids Res. 19:747-750 | |
| | | SIGWART, et al. (1989) "Effect of purA mutation on efficacy of Salmonella live-vaccine vectors," Infect. Immun. 57:1858-1861 | |
| | | SKORUPSKI and TAYLOR (1996) "Positive selection vectors for allelic exchange," Gene 169:47-52 | |
| | | STRUGNELL et al (1990) "Stable expression of foreign antigens from the chromosome of Salmonella typhimurium vaccine strains," Gene 88:57-63. ABSTRACT ONLY | |
| | | STRUGNELL et al. (1992) "Characterization of a Salmonella typhimurium aro vaccine strain expressing the p69 antigen of Bordetella pertussis," Infect. Immun. 60:3994-4002 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | SU et al. (1992) "Extracellular export of Shiga toxin B-subunit haemolysin A (C-terminus) fusion proteins expressed in Salmonella typhimurium aro-A mutant and stimulation of B-subunit specific antibody responses," Microb. Pathog. 13:465-476. ABSTRACT ONLY | |
| | | SULLIVAN et al (1993) "Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model," Antimicrob. Agents Chemother. 37:234-239 | |
| | | TACKET et al. (1990) "Safety and immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi21a" Infect. Immun. 58:1620-1627 | |
| | | TACKET et al. (1997) "Safely and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system," Infect. Immun. 65:3381-3385 | |
| | | TAKEUCHI (1967) "Electron microscope studies of experimental Salmonella infection. I. Penetration into the intestinal epithelium by Salmonella typhimurium," Am. J. Pathol. 50:109-136 | |
| | | TANG et al. (1993) "Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity," Nucleic Acids Res. 21:2729-2735 | |
| | | TIJHAAR et al. (1997) "Induction of feline immunodeficiency virus specific antibodies in cats with an attenuated Salmonella strain expressing the Gag protein," Vaccine 15:587-596 | |
| | | TIJHAAR et al. (1997) "Salmonella typhimurium aroA recombinants and immune-stimulating complexes as vaccine candidates for feline immunodeficiency virus," J. Gen. Virol. 46:129-138 | |
| | | UZNANSKI et al. (1987) "Deoxyribonucleoside 3'-phosphordiamidites as substrates for solid supported synthesis of oligodeoxyribonucleotides," Tetrahedron Letters 28:3401-3404 | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|---|----------------|
| | | VALENTINE et al. (1996) "Induction of SIV capsid specific CTL and mucosal sIgA in mice immunized with recombinant S. typhimurium aroA mutant," Vaccine 14:138-146 | |
| | | VAN GIJSEGEEM et al (1993) "Conservation of secretion pathways for pathogenicity determinants of plant and animal bacteria," Trends Microbiol. 1:175-180 | |
| | | VEBER et al. (1993) "Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia," J. Antimicrob. Chemother. 32:473-483 | |
| | | VENKATESAN et al. (1992) "Surface presentation of Shigella flexneri invasion plasmid antigens requires the products of the spa locus," J. Bacteriol. 174:1990-2001 | |
| | | VERMA et al. (1995) "Induction of a cellular immune response to a defined T cell epitope as an insert in the flagellin of a live vaccine strain of Salmonella," Vaccine 13:235-234. ABSTRACT ONLY | |
| | | VILLAFANE et al. (1987) "Replication control genes of plasmid pE194," J. Bacteriol. 169:4822-4829 | |
| | | VIRET et al. (1993) "Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains." Mol. Microbiol. 7:239-252. ABSTRACT ONLY | |
| | | WANG et al, (2006) "Application of signature tagged mutagenesis to the study of Erwinia amylovora" FEMS Microbiol. Lett. 265:164-171 | |
| | | WATTIAU et al. (1994) "Individual chaperones required for Yop secretion by Wattiau et al. (1994) "Individual chaperones required for Yop secretion by Yersinia" PNAS 91:10493-10497 | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|---|----------------|
| | | WHITMAN et al (1993) "Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium," Antimicrob. Agents Chemother. 37:2069-2073 | |
| | | WHITTLE et al. (1997) "Immune response to a Murray Valley encephalitis virus epitope expressed in the flagellin of an attenuated strain of Salmonella," J. Med. Microbiol. 46:129-138 | |
| | | WHITTLE AND VERMA (1997) "The immune response to a B-cell epitope delivered by Salmonella is enhanced by prior immunological experience," Vaccine 15:1737-1740. ABSTRACT ONLY | |
| | | WIRTH et al. (1986) "Highly efficient protoplast transformation system for Streptococcus faecalis and a new Escherichia coli-S. Faecalis shuttle vector," J. Bacteriol. 165:831-836 | |
| | | WOODS et al. (1982) "Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats," Infect. Immun. 36:1223-1228 | |
| | | YAN et al. (1996) "Mixed population approach for vaccination with live recombinant Salmonella strains," J. Biotechnol. 44:197-201. ABSTRACT ONLY | |
| | | YANCEY (1993) "Recent advances in bovine vaccine technology," J. Dairy Sci. 76:2418-2436 | |
| | | YANG et al., (1990) "Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis," J. Immunol. 145:2281-2285. ABSTRACT ONLY | |
| | | YANISCH-PERRON et al. (1985) "Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors." Gene 33:103-119 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 24 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | YOUDERAIN et al. (1988) "Packaging specific segments of the Salmonella chromosome locked-in Mud-P22 prophages," Genetics, 118:581-592 | |
| | | YOUNG et al (1999) "A new pathway for the secretion of virulence factors by bacteria: the flagellar export apparatus functions as a protein secretion system." PNAS 96:6456-6461 | |
| | | ZHU et al. (1993) "Systemic gene expression intravenous DNA delivery into adult mice." Science 261:209-211 | |
| | | ACHARYA et al. (1987) "Prevention of typhoid fever in nepal with the vi capsular polysaccharide of <i>Salmonella typhi</i> ," NEJM, 317:1101-1104 | |
| | | AHMER et al. (1999) " <i>Salmonella</i> SirA is a global regulator of genes mediating enteropathogenesis," Mol. Microbiol. 31(3):971-982. | |
| | | ALTARE et al. (1998) "Inherited interleukin 12 deficiency in a child with Bacille Calmette-Guerin and <i>Salmonella enteritidis</i> disseminated infection," J. Clin. Invest. 102:2035-2040 | |
| | | ANGELAKOPOULOS and HOHMANN (2000) "Pilot study of <i>phoP/phoQ</i> -deleted <i>Salmonella enterica</i> serovar Typhimurium expressing <i>Helicobacter pylori</i> urease in adult volunteers," Infect. Immun., 68:2134-2141. | |
| | | ARANDA et al. (1992) " <i>Salmonella typhimurium</i> activates virulence gene transcription within acidified macrophage phagosomes," PNAS, 89:10079-10083 | |
| | | ARRICAU et al. (1998) "The RcsB-RcsC regulatory system of <i>Salmonella typhi</i> differentially modulates the expression of invasion proteins, flagellin and Vi antigen in response to osmolarity," Mol. Microbiol. 29:835-850. | |
| | | ASCON, et al. (1998) "Oral immunization with a <i>Salmonella typhimurium</i> vaccine vector expressing recombinant enterotoxigenic <i>Eschericia coli</i> K99 fimbriae elicits elevated antibody titers for protective immunity," Infect. Immun. 66:5470-5476 | |
| | | ATTRIDGE (1991) "Oral immunization with <i>Salmonella typhi</i> Ty21a-based clones expressing <i>Vibrio cholerae</i> O-antigen: serum bactericidal antibody responses in man in relation to pre-immunization antibody levels," Vaccine, 9:877-882 | |

| | |
|---------------------|-----------------|
| Examiner Signature: | Date Considered |
|---------------------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 25 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | BAO and CLEMENTS (1991) "Prior immunologic experience potentiates the subsequent antibody response when <i>Salmonella</i> strains are used as vaccine carriers," Infect. Immun. 59:3841-3845 | |
| | | BARRY et al. (1996) "Expression and Immunogenicity of Pertussis Toxin S1 subunit-tetanus toxin fragment C fusion in <i>Salmonella typhi</i> vaccine strain CVD 908," Infect. Immun. 64:7472-4781. | |
| | | BASSO et al. (2002) "Characterization of a novel intracellularly activated gene from <i>Salmonella enterica</i> serovar typhi," Infect. Immun. 70:5404-5411 | |
| | | BENJAMIN et al. (1991) "A <i>hemA</i> mutation renders <i>Salmonella typhimurium</i> avirulent in mice, yet capable of eliciting protection against intravenous infection with <i>S. typhimurium</i> ," Microb. Pathog. 11:289-295. | |
| | | BEUZON et al. (1999) "pH-dependant secretion of SseB, a product of the SPI-2 type III secretion system of <i>Salmonella typhimurium</i> ," Mol. Microbiol. 33:806-816 | |
| | | BEUZON et al. (2000) " <i>Salmonella</i> maintains the integrity of its intracellular vaciole through the action of SifA," EMBO J., 19:3235-3249 | |
| | | BLACK, et al. (1983) "Immunogenicity of Ty21a Attenuated <i>Salmonella typhi</i> given with sodium bicarbonate or in enteric-coated capsules," Develop. Biol. Stand., 53:9-14. | |
| | | BOST and CLEMENTS (1995) "In vivo induction of interleukin-12 mRNA epxression after oral immunization with <i>Salmonella dublin</i> or the B subunit of <i>Escherichia coli</i> heat-labile enterotoxin," Infect. Immun. 63:1076-1083 | |
| | | BRENNAN et al. (1994) "Differences in the immune responses of mice and sheeo ti an aromatic-dependent mutant of <i>Salmonella typhimurium</i> ," J. Med. Microbiol. 41:20-28 | |
| | | BROWN and HORMAECHE (1989) "The antibody response to salmonellae in mice and humans studied y immunoblots and ELISA," Microb. Pathog. 6:445-454 | |
| | | BROWN et al. (1987) "An attenuated <i>aroA</i> <i>Salmonella typhimurium</i> vaccine elicits humoral and cellular immunity to cloned β -galactosidase in mice," J. Infect. Dis. 155:86-92 | |
| | | BROWNE et al. (2002) "Genetic requirements for <i>Salmonella</i> -induced cytopathology in human monocyte-derived macrophages," Infect. Immun. 70:7126-7135 | |
| | | BUCHMEIER and LIBBY (1997) "Dynamics of growth and death within a <i>Salmonella typhimurium</i> population during infection of macrophages," Can. J. Microbiol. 43:29-34 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | BUMANN et al. (2000) "Recombinant live <i>Salmonella</i> spp. for human vaccination against heterologous pathogens," FEMS Immunol. Med. Microbiol. 27:357-364 | |
| | | BUMANN et al. (2002) "Safety and immunogenicity of live recombinant <i>Salmonella enterica</i> serovar typhi Ty21a expressing urease A and B from <i>Helicobacter pylori</i> in human volunteers," Vaccine, 20:845-852. | |
| | | BUTLER, et al. (1991) "Pattern of morbidity and mortality in typhoid fever dependent on age and gender: review of 552 hospitalized patients with diarrhea," Rev. Infect. Dis. 13:85-90. | |
| | | CAMERON and FULS (1976) "Immunizaion of mice and calves agaist <i>Salmonella dublin</i> with attenuated live and inactivated vaccines," J. Vet. Res. 43:31-38 | |
| | | CANCELLIERI and FARA (1985) "Demonstration of specific IgA in human feces after immunization with live Ty21a <i>Salmonella typhi</i> vaccine," J. Infect. Dis. 151:482-484 | |
| | | CARO, et al. (1999) "Physiological changes of <i>Salmonella typhimurium</i> cells under osmotic and starvation conditions by image analysis," FEMS Microbiol. Lett. 179:265-273 | |
| | | CARRIER, et al. (1992) "Expression of Human IL-1 β in <i>Salmonella typhimurium</i> , a model system for the delivery of recombinant therapeutic proteins in vivo," J. Immunol. 148:176-181 | |
| | | CARTER and COLLINS (1974) "Growth of typhoid and paratyphoid Bacilli in travenously infected mice," Infect. Immun. 10:816-822 | |
| | | CASADEVALL (1998) "Antibody-mediated protection against intracellular pathogens," Trends in Microbiol. 6:102-107 | |
| | | CHABALGOITY et al. (1995) "Influence of preimmunization with tetanus toxoid on immune responses to tetanus toxin fragment c-guest antigen fusions in <i>Salmonella</i> vaccine carrier," Infect. Immun. 63:2564-2569 | |
| | | CHABALGOITY et al. (1997) "Expression and immunogenicity of an <i>Echinococcus granulosus</i> fatty acid-binding protein in live attenuated <i>Salmonella</i> vaccine strains," Infect. Immun. 65:2402-2412 | |
| | | CHARLES et al. (1990) "Isolation, characterization and nucleotide sequences of the <i>aroC</i> genes encoding chorismate synthase from <i>Salmonella typhi</i> and <i>Escherichia coli</i> ," J. Gen. Microbiol. 136:353-358 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number. | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | CHATFIELD, et al. (1992) "Use of the <i>nirB</i> promoter to direct the stable expression of heterologous antigens in <i>Salmonella</i> oral vaccine strains: development of a single-dose oral tetanus vaccine," Biotechnol. 10:888-892 | |
| | | CHATFIELD, et al. (1992) "Evaluation of <i>Salmonella typhimurium</i> strains harbouring defined mutations in <i>htrA</i> and <i>aroA</i> in the murine salmonellosis model," Microbial Pathog. 12:145-151 | |
| | | CHATFIELD, et al. (1994) "Progress in Development of Multivalent Oral Vaccines Based on Live Attenuated <i>Salmonella</i> " in <i>Modern Vaccinology</i> E. Kurstak, ed., Plenum Medical, New York, NY. 55-85 | |
| | | CHEN and SCHIFFERLI (2001) "Enhanced immune responses to viral epitopes by combining macrophage-inducible expression with multimeric display on a <i>Salmonella</i> vector," Vaccine, 19:3009-3018 | |
| | | CHEN, et al (1996) "Salmonella spp. are cytotoxic for cultured macrophages," Mol. Microbiol. 21:1101-1115 | |
| | | CHUTTANI, et al. (1973) "Ineffectiveness of an oral killed typhoid vaccine in a field trial," Bull. Org. Mond. Sante, 48:756-757 | |
| | | CHUTTANI, et al. (1977) "Controlled field trial of a high-dose oral killed typhoid vaccine in India," WHO 55:643-644. | |
| | | CIACCI-WOOLWINE et al. (1997) "Salmonellae activate tumor necrosis factor alpha production in a human promonocytic cell line via a released polypeptide," Infect. Immun. 65:4624-4633 | |
| | | CIESLAK et al. (1993) "Expression of a recombinant <i>Entamoeba histolytica</i> antigen in a <i>Salmonella typhimurium</i> vaccine strain," Vaccine 11:773-776 | |
| | | CLAIRMONT et al. (2000) "Biodistribution and genetic stability of the novel antitumor agent VPN20009, a genetically modified strain of <i>Salmonella typhimurium</i> " J. Infect. Dis. 181:1996-2002 | |
| | | CLARK, et al. (1996) "Invasion of murine intestinal M cells by <i>Salmonella typhimurium inv</i> mutants severely deficient for invasion of cultured cells," Infect. Immun. 64:4363-4368 | |
| | | CLARK, et al. (1998) "Inoculum composition and <i>Salmonella</i> pathogenicity island 1 regulate M-cell invasion and epithelial destruction by <i>Salmonella typhimurium</i> ," Infect. Immun. 66:724-731 | |
| | | CLEMENTS and EL-MORSHIDY (1984) "Construction of a potential live oral bivalent vaccine for typhoid fever and cholera- <i>Escherichia coli</i> -Related diarrheas," Infect. Immun. 46:564-569 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | CLEMENTS et al. (1986) "Oral immunization of mice with attenuated <i>Salmonella enteritidis</i> containing a recombinant plasmid which codes for production of the B subunit of heat-labile <i>Escherichia coli</i> enterotoxin," Infect. Immun. 53:685-692 | |
| | | COBELENS, et al. (2000) "Typhoid fever in groups of travelers: Opportunity for studying vaccine efficacy," J. Travel Med. 7:19-24 | |
| | | COLLINS and CARTER (1972) "Comparative immunogenicity of heat-killed and living oral <i>Salmonella</i> vaccines," Infect. Immun. 6:451-458 | |
| | | COLLINS (1972) "Salmonellosis in orally infected specific pathogen-free C57Bl mice," Infect. Immun. 5:191-198 | |
| | | COOPER et al. (1992) "Vaccination of chickens with chicken-derived <i>Salmonella enteritidis</i> phage type 4 <i>aroA</i> live oral salmonella vaccines," Vaccine 10:247-254 | |
| | | CORBEL (1996) "Reasons for instability of bacterial vaccines," Dev. Biol. Stand. 87:113-124. | |
| | | COULSON et al. (1994) " <i>Bacillus anthracis</i> protective antigen, expressed in <i>Salmonella typhimurium</i> SL 3261, affords protection against anthrax spore challenge," Vaccine, 12:1395-1401 | |
| | | COULSON et al. (1994) "Effect of different plasmids on colonization of mouse tissues by the aromatic amino acid dependent <i>Salmonella typhimurium</i> , SL 3261," Microbial Pathog. 16:305-311 | |
| | | COYNAULT and NORAL (1999) "Comparison of the abilities of <i>Salmonella typhimurium rpoS</i> , <i>aroA</i> and <i>rpoS aroA</i> strains to elicit humor immune responses in BALB/c mice to cause lethal infection in athymic BALB/c mice," Microbial Pathog. 26:299-305 | |
| | | COYNAULT et al. (1996) "Virulence and vaccine potential of <i>Salmonella typhimurium</i> mutants deficient in the expression of the RpoS σ^5 regulon," Mol. Microbiol. 22:149-160 | |
| | | CRYZ et al. (1989) "Construction and characterization of a Vi-positive variant of the <i>Salmonella typhi</i> live oral vaccine strain Ty21a," Infect. Immun. 57:3863-3868 | |
| | | CRYZ et al. (1995) "Safety and immunogenicity of a live oral bivalent typhoid fever (<i>Salmonella typhi</i> Ty21a)-cholera (<i>Vibrio cholerae</i> CVD 103-HgR) vaccine in healthy adults," Infect. Immun. 63:1336-1339 | |
| | | CURTISS and KELLY (1987) " <i>Salmonella typhimurium</i> deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic," Infect. Immun. 55:3035-3043 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | CURTISS et al. (1989) "Recombinant avirulent <i>Salmonella</i> vaccine strains with stable maintenance and high level expression of cloned genes in vivo," Immunol. Invest. 18:583-596 | |
| | | D'AMELIO et al. (1988) "Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines," Infect. Immun.. 56:2731-2735 | |
| | | DE ALMEIDA (1999) "Antibody responses against flagellin in mice orally immunized with attenuated <i>Salmonella</i> vaccine strains," Arch. Microbiol. 172:102-108 | |
| | | DHAM and THOMPSON (1982) "Studies of cellular and humoral immunity in typhoid fever and TAB vaccinated subjects," Clin. Exp. Immunol. 48:389-395. | |
| | | DILTS, et al. (2000) "Phase I clinical trials of <i>aroA aroD</i> and <i>aroA aroD htrA</i> attenuated <i>S. typhi</i> vaccines; effect of formulation on safety and immunogenicity," Vaccine, 18:1473-1484 | |
| | | DIMA (1981) "Isolation and characterization of two <i>Salmonella typhosa</i> mutants for possible use as a live oral attenuated vaccinal strains," Arch. Roum. Path. Exp. Microbiol. 40:33-40 | |
| | | DEPETRILLO (2000) "Safety and immunogenicity of <i>PhoP/PhoQ</i> -deleted <i>Salmonella typhi</i> expressing <i>Helicobacter pylori</i> urease in adult volunteers," Vaccine 18:449-459. | |
| | | DJAVANI et al. (2001) "Mucosal immunization with <i>Salmonella typhimurium</i> expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus," J. Hum. Virol. 4:103-108 | |
| | | DORMAN et al. (1989) "Characterization of porin and <i>ompR</i> mutants of a virulent strain of <i>Salmonella typhimurium</i> : <i>ompR</i> mutants are attenuated in vivo," Infect. Immun. 57:2136-2140 | |
| | | DORNER (1995) "An overview of vaccine vectors," Dev. Biol. Stand. 84:23-32 | |
| | | DOUCE, et al. (1991) "Invasion of HEp-2 cells by strains of <i>Salmonella typhimurium</i> different virulence in relation to gastroenteritis," J. Med. Microbiol. 35:349-357 | |
| | | DOUGAN, et al. (1988) "Construction and characterization of vaccine strains of <i>Salmonella</i> harboring mutations in two different <i>aro</i> genes," J. Infect. Dis. 158:1329-1335 | |
| | | DRAGUNSKY et al. (1990) "In vitro characterization of <i>Salmonella typhi</i> mutant strains for live oral vaccines," Vaccine 8:263-268 | |
| | | DRAGUNSKI et al. (1989) "Salmonella typhi vaccine strain in vitro; low infectivity in human cell line U937," J. Biol. Stand. 17:353-360. | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | DUNSTAN et al. (1999) "Use of in vivo-regulated promoters to deliver antigens from attenuated <i>Salmonella enterica</i> var. Typhimurium," Infect. Immun. 67:5133-5141 | |
| | | DUPONT et al. (1971) "Studies of immunity in typhoid fever," Bull. Org. Mond. Sante. 44:667-672 | |
| | | EDWARDS and STOCKER (1988) "Construction of Δ aroA his Δ pur strains of <i>Salmonella typhi</i> ," J. Bacteriol. 170:3991-3995 | |
| | | EICHELBERG and GALAN (1999) "Differential regulation of <i>Salmonella typhimurium</i> type III secreted proteins by pathogenicity island 1 (SPI-1)-encoded transcriptional activators InvF and HilA," Infect. Immun. 67:4099-4105 | |
| | | EMMERTH, et al. (1999) "Genomic subtraction identifies <i>Salmonella typhimurium</i> prophages, F-related plasmid sequences, and a novel fimbrial operon, stf, which are absent in <i>Salmonella typhi</i> ," J. Bacteriol. 181:5652-5661 | |
| | | ENGELS, et al. (1998) "Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity," BMJ, 316:110-113 | |
| | | EVEREST, et al. (1999) "Evaluation of <i>Salmonella typhimurium</i> Mutants in a model of experimental gastroenteritis," Infect. Immun. 67:2815-2821. | |
| | | FALLON, et al. (1991) "Mouse hepatitis virus strain UAB infection enhances resistance to <i>Salmonella typhimurium</i> in mice by inducing suppression of bacterial growth," Infect. Immun. 59:852-856. | |
| | | FERRICIO (1989) "Comparative efficacy of two, three or four doses of TY21a live oral vaccine in enteric coated capsules: a field trial in an endemic area," J. Infect. Dis. 159:766-769 | |
| | | FINLAY and FALKOW (1997) "Common themes in microbial pathogenicity revisited," Microbiol. Mol. Biol. Rev. 61:136-169. | |
| | | FORMAL et al. (1981) "Construction of a potential bivalent vaccine strain: introduction of <i>Shigella sonnei</i> form I antigen genes into the <i>galE</i> <i>Salmonella typhi</i> Ty21a typhoid vaccine strain," Infect. Immun. 34:746-750 | |
| | | FORREST and LaBrooy (1993) "Effect of parenteral immunization on intestinal immune response to <i>Salmonella typhi</i> Ty21a as measured using peripheral blood lymphocytes," Vaccine, 11:136-139 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | FU and GALAN (1998) "The <i>Salmonella typhimurium</i> tyrosine phosphatase SptP is translocated into host cells and disrupts the actin cytoskeleton," Mol. Microbiol. 27:359-368 | |
| | | GAHRING, et al. (1990) "Invasion and replication of <i>Salmonella typhimurium</i> in animal cells," Infect. Immun. 58:443-448 | |
| | | GALAN and COLIMER (1999) "Type III secretion machines: bacterial devices for protein delivery into host cells," Science, 284:1322-1328 | |
| | | GALAN and ZHOU (2000) Striking a balance: modulation of the actin cytoskeleton by <i>Salmonella</i> . PNAS, 97:8754-8761 | |
| | | GALAN, et al (1990) "Cloning and characterization of the <i>asd</i> gene of <i>Salmonella typhimurium</i> : use in a stable maintenance of recombinant plasmids in <i>Salmonella</i> vaccine strains," Gene, 94:29-35 | |
| | | GALAN and LEVINE (2001) "Can a 'flawless' love vector strain be engineered?" Trends in Microbiol. 9:372-376 | |
| | | GALAN (1996) "Molecular genetic bases of <i>Salmonella</i> entry into host cells," Mol. Microbiol. 20:263-271 | |
| | | GALEN et al. (1999) "Optimization of plasmid maintenance in attenuated live vector vaccine strain <i>Salmonella typhi</i> CVD 908- <i>htrA</i> " Infect. Immun. 67:6424-6433 | |
| | | GARCIA-DEL PORTILLO, et al. (1993) " <i>Salmonella</i> induces the formation of filament structures containing lysosomal membrane glycoproteins in epithelial cells," PNAS, 90:10544-10548 | |
| | | GARMORY et al. (2002) " <i>Salmonella</i> vaccines for use in humans: present and future perspectives," FEMS Microbiol. Rev. 26:339-353 | |
| | | GAUTIER et al. (1998) "Mouse susceptibility to infection by the <i>Salmonella abortusovus</i> vaccine strain Rv6 is controlled by the <i>Ity/Nramp 1</i> gene and influences the antibody response but not the complement response," Microbial Pathog. 24:47-55 | |
| | | GENTSCHEV et al. (2000) "Delivery of protein antigens and DNA by virulence attenuated strains of <i>Salmonella typhimurium</i> and <i>Listeria monocytogenes</i> ," J. Bacteriol. 83:19-26 | |
| | | GERMANIER and FURER (1975) "Isolation and characterization of <i>Gal E</i> mutant Ty21a of <i>Salmonella typhi</i> : a candidate strain for a live oral typhoid vaccine," J. Infect. Dis. 131:553-558 | |
| | | GERMANIER and LEVINE (1986) "The live typhoid vaccine Ty21a: recent field trial results," Bacterial Vaccines and Local Immunity:19-22 | |

| | |
|---------------------|-----------------|
| Examiner Signature: | Date Considered |
|---------------------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|--|----------------|
| | | GEWIRTZ et al (1999) "Orchestration of neutrophil movement by intestinal epithelial cells in response to <i>Salmonella typhimurium</i> can be uncoupled from bacterial internalization," Infect. Immun. 67:608-617 | |
| | | GILMAN (1977) "Evaluation of UDP-glucose-4-epimeraseless mutant of <i>Salmonella typhi</i> as a live oral vaccine," J. Infect. Dis. 130:717-723 | |
| | | GIRON et al. (1995) "Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic <i>Escherichia coli</i> by Δ aroC, Δ aroD <i>Salmonella typhi</i> vaccine strain CVD 908," Vaccine, 13:939-946 | |
| | | GONZALES, et al. (1994) " <i>Salmonella typhi</i> vaccine strain CVD 908 expressing the circumsporozoite protein of <i>Plasmodium falciparum</i> : Strain construction and safety and immunogenicity in humans," J. Infect. Dis. 169:927-931 | |
| | | GONZALES et al. (1998) "Immunogenicity of a <i>Salmonella typhi</i> CVD 908 candidate vaccine strain expressing the major surface protein gp63 of <i>Leishmania mexicana mexicana</i> ," Vaccine 16:1043-1052 | |
| | | GROSSMAN et al. (1995) "Flagellar serotypes of <i>Salmonella typhi</i> in Indonesia: Relationships among motility, invasiveness, and clinical illness" J. Infect. Dis. 171:212-216 | |
| | | GUARD-PETTER, et al. (1995) "Characterization of lipopolysaccharide heterogeneity in <i>Salmonella enteritidis</i> by an improved gel electrophoresis method," Appl. Environ. Microbiol., 61:2845-2851 | |
| | | GUERRANT and KOSEK (2001) "Polysaccharide conjugate typhoid vaccine," NEJM, 344:1322-1323 | |
| | | GUILLOBEL et al. (2000) "Adjuvant activity of a nontoxic mutant <i>Escherichia coli</i> heat-labile enterotoxin on systemic and mucosal immune responses elicited against a heterologous antigen carried by a live <i>Salmonella enterica</i> serovar typhimurium vaccine strain," 68:4349-4353. | |
| | | GUNN et al. (1995) "Characterization of the <i>Salmonella typhimurium</i> pagC/pagD Chromosomal region," J. Bacteriol. 177:5040-5047 | |
| | | GUO et al. (1997) "Regulation of lipid modifications by <i>Salmonella typhimurium</i> virulence genes <i>phoP-phoQ</i> ," Science, 276:250-253 | |
| | | HACKET (1993) "Use of <i>Salmonella</i> for heterologous gene expression and vaccine delivery systems," Curr. Opin. Biotechnol. 4:611-615. | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|--|----------------|
| | | HALL and TAYLOR (1970) "Salmonella Dublin: The relation between a living calf vaccine strain and those isolated from human and other sources," Vet. Rec. 86:534-536. | |
| | | HARRISON et al. (1997) "Correlates of protection induced by live Aro ⁻ <i>Salmonella typhimurium</i> vaccines in the murine typhoid model," Immunol. 90:618-625 | |
| | | HERRINGTON et al. (1990) "Studies in volunteers to evaluate candidate <i>Shigella</i> vaccines: further experience with a bivalent <i>Salmonella typhi</i> - <i>Shigella sonnei</i> vaccine and protection conferred by previous <i>Shigella sonnei</i> disease," Vaccine, 8:353-357 | |
| | | HESS et al. (1996) " <i>Salmonella typhimurium</i> aroA ⁻ infection in gene-targeted immunodeficient mice; major role of CD4 ⁺ TCR-αβ cells in IFN-γ in bacterial clearance independent of intracellular location," J. Immunol. 156:3321-3326 | |
| | | HINDLE et al. (2002) "Characterization of <i>Salmonella enterica</i> derivatives harboring defined aroC and <i>Salmonella</i> pathogenicity island 2 type III secretion system (<i>ssaV</i>) mutations by immunization of healthy volunteers," Infect. Immun. 70:3457-3467 | |
| | | HIROSE et al. (1997) "Survival of Vi-capsulated and Vi-deleted <i>Salmonella typhi</i> strains in cultured macrophage expressing different levels of CD14 antigen," FEMS Microbiol. Lett. 147:259-265 | |
| | | HOHMANN and OLETTA (1996) " <i>phoP/phoQ</i> - deleted <i>Salmonella typhi</i> (Ty800) is safe and immunogenic single-dose fever vaccine in volunteers," J. Infect. Dis. 173:1408-1414 | |
| | | HOISTH and STOCKER (1981) "Aromatic-dependent <i>Salmonella typhimurium</i> are non-virulent and effective as live vaccines," Nature, 291:238-239 | |
| | | HOLDEN (2002) "Trafficking of the <i>Salmonella</i> vacuole in macrophages," Traffic, 3:1-11 | |
| | | HOLMSTROM, et al. (1999) "Physiological states of individual <i>Salmonella typhimurium</i> cells monitored by in situ reverse transcription PCR," J. Bacteriol. 181:1733-1738 | |
| | | HONE et al. (1988) "A <i>galE</i> via (Vi antigen-negative) mutant <i>Salmonella typhi</i> Ty2 retains virulence in humans," Infect. Immun. 56:1326-1333. | |
| | | HONE et al. (1991) "Construction of genetically defined double aro mutants of <i>Salmonella typhi</i> ," Vaccine, 9:810-816 | |
| | | HONE et al. (1992) "Evaluation in volunteers of candidate live oral attenuated <i>Salmonella typhi</i> vector vaccine," J. Clin. Invest. 90:412-420 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 34 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | HONE, et al. (1994) "Adaptive acid tolerance response by <i>Salmonella typhi</i> and candidate live oral typhoid vaccine strains," Vaccine, 12:895-898 | |
| | | HOPKINS, et al. (1995) "A recombinant <i>Salmonella typhimurium</i> vaccine induces local immunity by four different routes of immunization," Infect. Immun. 63:3279-3286 | |
| | | HORMAECHE (1979) "Natural resistance to <i>Salmonella typhimurium</i> in different inbred mouse strains," Immunol. 37:311-318 | |
| | | HORNICK (1970) "Typhoid fever: pathogenesis and immunologic control," NEJM, 283: 739-742. | |
| | | HOUSE, et al. (2001) "Typhoid fever: pathogenesis and disease," Curr. Opin. Infect. Dis. 14:573-578. | |
| | | HUMPHREYS, et al. (1999) The alternative sigma factor, σ^E is critically important for the virulence of <i>Salmonella typhimurium</i> ," Infect. Immun. 67:1560-1568 | |
| | | ISHIBASHI and ARAI (1995) " <i>Salmonella typhi</i> does not inhibit phagosome-lysosome fusion in human monocyte derived macrophages," FEMS Immunol. Med. Microbiol. 12:55-62 | |
| | | IVANOFF, et al. "Vaccination against typhoid fever: present status," WHO Bull. DMS, 72:957-971 | |
| | | JEPSON et al. (1996) "Evidence for a rapid, direct effect on epithelial monolayer integrity and transepithelial transport in response to <i>Salmonella</i> invasion," Eur. J. Physiol. 432:225-233. | |
| | | JOHNSTON et al. (1996) "Transcriptional activation of <i>Salmonella typhimurium</i> invasion genes by a member of the phosphorylated response-regulator superfamily," Mol. Microbiol. 22:715-727. | |
| | | JONES et al. (1981) "The invasion of HeLa cells by <i>Salmonella typhimurium</i> : Reversible and irreversible bacterial attachment and the role of bacterial motility," J. Gen. Microbiol. 127:351-360. | |
| | | KANTELE, et al. (1991) "Comparison of the human immune response to live oral, killed oral or killed parenteral <i>Salmonella typhi</i> Ty21A vaccines," Microbial Pathog. 10:117-126 | |
| | | KANTELE et al. (1998) "Differences in immune responses induced by oral and rectal immunizations with <i>Salmonella typhi</i> TY21a: Evidence for compartmentalization within the common mucosal immune system in humans," Infect. Immun. 66:5630-5635 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | KAREM, et al. (1995) "Differential induction of carrier antigen-specific immunity by <i>Salmonella typhimurium</i> live-vaccine strains after single mucosal or intravenous immunization of Balb/c mice," Infect. Immun. 63:4557-4563 | |
| | | KAREM, et al. (1997) "Protective immunity against herpes simplex (HSV) type 1 following oral administration of recombinant <i>Salmonella typhimurium</i> vaccine strains expressing HSV antigens," J. Gen. Virol. 78:427-434. | |
| | | KAUFMAN and HESS (1999) "Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development," Immunol. Lett. 65:81-84. | |
| | | KAWAKAMI, et al. (1969) "Experimental Salmonellosis immunizing effect of live vaccine prepared from various mutants of <i>Salmonella</i> having different cell wall polysaccharides," Japan. J. Microbiol. 13:315-324 | |
| | | KEDDY, et al. (1998) "Efficacy of Vi polysaccharide vaccine against strains of <i>Salmonella typhi</i> : reply" Vaccine, 16:871-872 | |
| | | KEHRES, et al. (2000) "The NRAMP proteins of <i>Salmonella typhimurium</i> and <i>Escherichia coli</i> are selective manganese transporters involved in the response to reactive oxygen," Mol. Microbiol. 36:1085-1100. | |
| | | KEITEL, et al. (1994) "Clinical and serological responses following primary and booster immunizations with <i>Salmonella typhi</i> Vi capsular polysaccharide vaccines," 12:195-199 | |
| | | KELLY, et al. (1992) "Characterization and protective properties of attenuated mutants of <i>Salmonella choleraesuis</i> ," Infect. Immun. 60:4881-4890 | |
| | | KEREN, et al. (1978) "The role of peyer's patches in the local immune response of rabbit ileum to live bacteria," J. Immunol. 120:1892-1896 | |
| | | KHAN, et al. (1998) " <i>Salmonella typhi</i> rpoS mutant is less cytotoxic than the parent strain but survives inside resting THP-1 macrophages," FEMS Microbiol. Lett. 161:201-208 | |
| | | KHAN et al. (1998) "A lethal role for lipid A in <i>Salmonella</i> infections," Mol. Microbiol. 29:571-579 | |
| | | KHAN et al. (2001) "Early responses to <i>Salmonella typhimurium</i> infection in mice occur at focal lesions in infected organs," Microbial Pathog. 30:29-38 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 36 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | KHAN et al. (2003) "Salmonella typhi and S. typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella pathogenicity island-2 (SPI-2) genes as vaccines and vectors," Vaccine, 21:538-548 | |
| | | KHAN, et al. (2007) "Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans," Vaccine, 25:4175-4182 | |
| | | KINGSLEY and BAUMLER (2000) "Host adaptation and the emergency of infectious disease: the Salmonella paradigm," 1006-1014 | |
| | | KIRKPATRICK, et al. (2005) "Comparison of the antibodies in lymphocyte supernatant and antibody-secreting cells assays for measuring intestinal mucosal immune response to a novel oral typhoid vaccine (M01ZH09)" Clin. Diagnostic Lab. Immunol. 12:1127-1129 | |
| | | KIRKPATRICK et al. (2005) "The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations," J. Infect. Dis. 192:360-366 | |
| | | KIRKPATRICK, et al. (2006) "Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers," Vaccine, 24:116-123 | |
| | | KLUGMAN, et al. (1987) "Protease activity of Vi capsular polysaccharide vaccine against typhoid fever," Lancet, 1165-1169 | |
| | | KOHBATA, et al. (1986) "Cytopathogenic effect of Salmonella typhi GIFU 10007 on M cells of murine ileal peyer's patches in ligated ileal loops: an ultrastructural study," Microbiol. Immunol. 30:1225-1237 | |
| | | KOHLER et al., (2000) "Effect of preexisting immunity to Salmonella on the immune response to recombinant Salmonella enterica serovar typhimurium expressing a Porphyromonas gingivalis hemagglutinin," Infect. Immun. 68:3116-3120 | |
| | | KOLLARITSCH et al. (1996) "Randomized double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines," Infect. Immun. 64:1454-1457 | |
| | | KOLLARITSCH et al. (1997) "Safety and immunogenicity of live oral Cholera and Typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccines, or yellow fever vaccine," J. Infect. Dis. 871-875 | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 37 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | KOLLARITSCH, et al. (2000) "Local and systemic immune responses to combined <i>Vibrio cholerae</i> CVD103-HgR and <i>Salmonella typhi</i> Ty21a live oral vaccines after primary immunization and reimmunization," Vaccine 18:3031-3039. | |
| | | KOTLOFF, et al. (1996) "Safety, immunogenicity, and transmissibility in humans in CVD 1203 a live oral <i>Shigella flexneri</i> 2a vaccine candidate attenuated by deletions in <i>aroA</i> and <i>virG</i> ," Infect. Immun. 64:4542-4548 | |
| | | KRAMER and VOTE (2000) "Granulocyte selected live <i>Salmonella enteritidis</i> vaccine is species specific," Vaccine, 18:2239-2243 | |
| | | LALMANACH and LANTIER (1999) "Host cytokine response and resistance to <i>Salmonella</i> infection," Microbes Infect. 1:719-726 | |
| | | LEBACQ (2001) "Comparative tolerability and immunogenicity of Typherix TM or Typhium Vi TM in healthy adults," Drugs, 15 Suppl. 1:5-12 | |
| | | LECLERC, et al. (1998) "Environmental regulation of <i>Salmonella typhi</i> invasion-defective mutants," Infect. Immun. 66:682-691 | |
| | | LEE and SCHNEEWIND (1999) "Type III secretion machines and the pathogenesis of enteric infections caused by <i>Yersinia</i> and <i>Salmonella</i> spp." Immunol. Rev. 168:241-255 | |
| | | LEE et al. (2000) "Surface-displayed viral antigens on <i>Salmonella</i> carrier vaccine," Nature Biotechnol. 18:645-648 | |
| | | LEE et al. (2000) "OmpR regulates the two-component system SsrA-SsrB in <i>Salmonella</i> pathogenicity island 2," J. Bacteriol. 182:771-781 | |
| | | LEHOUX et al. (1999) "Defined oligonucleotide tag pools and PCR screening in signature-tagged mutagenesis of essential genes from bacteria," BioTechniques 26:473-480 | |
| | | LEUNG and FINLAY (1991) "Intracellular replication is essential for the virulence of <i>Salmonella typhimurium</i> ," PNAS 88:11470-11474 | |
| | | LEVINE and SZTEIN (1996) "Human mucosal vaccines for <i>Salmonella typhi</i> infections," in <i>Mucosal Vaccines</i> , Kiyono, et al., eds. Academic Press, San Diego. | |
| | | LEVINE, et al. (1985) "The efficacy of attenuated <i>Salmonella typhi</i> oral vaccine strain Ty21a evaluated in controlled field trials," Dev. Vaccines and Drugs against diarrhea, 11 th Nobel Conf. Stockholm, pp.90-101 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | LEVINE et al. (1987) "Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of <i>Salmonella typhi</i> , 541Ty and 543Ty, as live oral vaccines in human," J. Clin. Invest. 79:888-902 | |
| | | LEVINE (1987) "Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation." Lancet, 1049-1052 | |
| | | LEVINE et al. (1989) "Progress in vaccines against typhoid fever," Rev. Infect. Dis. 11:S552-S567 | |
| | | LEVINE, et al. (1990) "Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial," Lancet, 336:891-894 | |
| | | LEVINE et al. (1997) "Attenuated <i>Salmonella typhi</i> and <i>Shigella</i> as live oral vaccines and as live vectors," Behring Inst. Mitt. 98:120-123 | |
| | | LEVINE, (1994) "Typhoid Fever Vaccines," in <u>Vaccines</u> , Plotkin and Mortimer, eds., W.B. Saunders Company, Philadelphia, 597-633 | |
| | | LEVINE, et al. (1999) "Duration of efficacy of Ty21a, attenuated <i>Salmonella typhi</i> live oral vaccine," Vaccine, 17:S22-S27 | |
| | | LEVINE, et al. (1997) "Attenuated <i>Salmonella</i> as a live vector for expression of foreign antigens. Part iii. <i>Salmonella</i> expressing protozoal antigens," in <u>New Generation Vaccines 2nd ed.</u> , Levine, et al., eds. Marcel Dekker, New York. 351-361 | |
| | | LEVINE et al. (2001) "Host- <i>Salmonella</i> interaction: human trials," Microbes Infect. 3:1271-1279 | |
| | | LIANG-TAKASAKI, et al. (1982) "Phagocytosis of bacteria by macrophages: Changing the carbohydrate of lipopolysaccharide alters interaction with complement and macrophages," J. Immunol. 128:1229-1235 | |
| | | LIANG-TAKASAKI et al. (1983) "Complement activation by polysaccharide of lipopolysaccharide: an important virulence determinant of <i>Salmonellae</i> ," Infect. Immun. 41:563-569 | |
| | | LIANG-TAKASAKI, et al. (1983) " <i>Salmonellae</i> activate complement differentially via the alternative pathway depending on the structure of their lipopolysaccharide O-antigen," J. Immunol. 130:1867-1870 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | LIBBY et al. (1994) "A cytolysin encoded by <i>Salmonella</i> is required for survival within macrophages," PNAS, 91:489-493 | |
| | | LIU, (1988) "Intact motility as <i>Salmonella typhi</i> invasion-related factor," Infect. Immun. 56:1967-1973 | |
| | | LODGE, et al. (1995) "Biological and genetic characterization of TnphoA mutants of <i>Salmonella typhimurium</i> TML in the context of gastroenteritis," Infect. Immun. 63:762-769 | |
| | | LONDONO et al. (1995) "Immunization of mice using <i>Salmonella typhimurium</i> expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen," Vaccine, 14:545-552 | |
| | | LOW, et al. (1999) "Lipid A mutant <i>Salmonella</i> with suppressed virulence and TNF α induction retain tumor-targeting in vivo," Nature Biotechnol. 17:37-41 | |
| | | LUCAS, et al. (2000) "Unravelling the mysteries of virulence gene regulation in <i>Salmonella typhimurium</i> ," Mol. Microbiol. 36:1024-1033 | |
| | | LUNDBERG, et al. (1999) "Growth phase-regulated induction of <i>Salmonella</i> -induced macrophage apoptosis correlates with transient expression of SPI-1 genes," J. Bacteriol. 181:3433-3437. | |
| | | MARSHALL, et al. (2000) "Use of the stationary phase inducible promoters, spv and dps, to drive heterologous antigen expression in <i>Salmonella</i> vaccine strains," Vaccine 18: 1298-1306 | |
| | | MASTROENI, et al. (1998) "Interleukin-12 Is Required for Control of the Growth of Attenuated Aromatic-Compound-Dependent <i>Salmonellae</i> in BALB/c Mice: Role of Gamma Interferon and Macrophage Activation," Infect. Immun. 66: 4767-4776 | |
| | | MASTROENI, et al. (1995) "Effect of Anti-Tumor Necrosis Factor Alpha Antibodies on Histopathology of Primary <i>Salmonella</i> Infections," Infect. Immun. 63: 3674-3682 | |
| | | MASTROENI, et al. (1992) "Role of T cells, TNF α and IFN γ in recall of immunity to oral challenge with virulent salmonellae in mice vaccinated with live attenuated aro- salmonella vaccines," Microbial Pathogen. 13: 477-491 | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SHEET 40 OF 51

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|---|----------------|
| | | MAZURKIEWICZ, et al. (2006) "Signature-tagged mutagenesis: barcoding mutants for genome-wide screens," Nat. Rev. Genet. 7: 929-939 | |
| | | MCFARLAND and STOCKER (1987) "Effect of different purine auxotrophic mutations on mouse-virulence of a Vi-positive strain of Salmonella dublin and of two strains of Salmonella typhimurium," Microbial Pathogen. 3: 129-141 | |
| | | MCSORLEY and JENKINS (2000) "Antibody Is Required for Protection against Virulent bu Not Attenuated Salmonella enterica Serovar Typhimurium," Infect. Immun. 68: 3344-3348 | |
| | | MEDINA and GUZMAN (2001) "Use of live bacterial vaccine vectors for antigen delivery: potential and limitations," Vaccine 19: 1573-1580 | |
| | | MIAO and MILLER (2000) "A conserved amino acid sequence directing intracellular type II secretion by Salmonella typhimurium," Proc. Natl. Acad. Sci. USA 97: 7539-7544 | |
| | | MILLS and FINLAY (1994) "Comparison of Salmonella typhi and Salmonella typhimurium invasion, intracellular growth and localization in cultured human epithelial cells," Microbial. Pathogen. 17: 409-423 | |
| | | MILLS, et al. (1998) "Trafficking of Porin-Deficient Salmonella typhimurium Mutants inside HeLa Cells: ompR and envZ Mutants Are Defective for the Formation of Salmonella-Induced Filaments," Infect. Immun. 66: 1806-1811 | |
| | | MINTZ, et al. (1983) "Effect of Lipopolysaccharide Mutations on the Pathogenesis of Experimental Salmonella Gastroenteritis," Infect. Immun. 40: 236-244 | |
| | | MITTRÜCKER and KAUFMANN (2000) "Immune response to infection with Salmonella typhimurium in mice," J. Leukoc. Biol. 67: 457-463 | |

| | |
|---------------------|-----------------|
| Examiner Signature: | Date Considered |
|---------------------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|---|----------------|
| | | MITTRÜCKER, et al. (2000) "Cutting Edge: Role of B Lymphocytes in Protective Immunity Against Salmonella typhimurium Infection," J. Immunol 164: 1648-1652 | |
| | | MOLLENKOPF, et al. (2001) "Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA," Vaccine 19: 4028-4035 | |
| | | MOLLENKOPF, et al. (2001) "Intracellular Bacteria as Targets and Carriers for Vaccination," Biol. Chem. 382: 521-532 | |
| | | NARDELLI-HAEFLIGER, et al. (2001) "Nasal vaccination with attenuated Salmonella typhimurium strains expressing the Hepatitis B nucleocapsid: dose response analysis," Vaccine 19: 2854-2861 | |
| | | NARDELLI-HAEFLIGER, et al. (1996) "Oral and Rectal Immunization of Adult Female Volunteers with a Recombinant Attenuated Salmonella typhi Vaccine Strain," Infect. Immun. 64: 5219-5224 | |
| | | NAUCIEL and ESPINASSE-MAES (1992) "Role of Gamma Interferon and Tumor Necrosis Factor Alpha in Resistance to Salmonella typhimurium Infection," Infect. Immun. 60: 450-454 | |
| | | NAUCIEL (1990) "Role of CD4+ T Cells and T-Independent Mechanisms in Acquired Resistance to Salmonella typhimurium Infection," J. Immunol. 145: 1265-1269 | |
| | | NICKERSON and CURTISS III, et al. (1997) "Role of Sigma Factor RpoS," in Initial Stages of Salmonella typhimurium Infection," Infect. Immun. 65: 1814-1823 | |
| | | ORNELLAS, et al. (1970) "The Specificity and Importance of Humoral Antibody in the Protection of Mice against Intraperitoneal Challenge with Complement-Sensitive and Complement-Resistant Salmonella," J. Infect. Disease 121: 113-123 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | PAESOLD, et al. (2002) "Genes in the Salmonella pathogenicity island 2 and the Salmonella virulence plasmid are essential for Salmonella-induced apoptosis in intestinal epithelial cells," Cell. Microbiol. 4: 771-781 | . |
| | | PAGLIA, et al. (2000) "In vivo correction of genetic defects of monocyte/macrophages using attenuated Salmonella as oral vectors for targeted gene delivery," Gene Therapy 7: 1725-1730 | |
| | | PANG, et al. (1995) "Typhoid fever and other salmonellosis: a continuing challenge," Trends Microbiol. 3: 253-255 | |
| | | PICKARD, et al. (1994) "Characterization of Defined ompR Mutants of Salmonella typhi: ompR Is Involved in the Regulation of Vi Polysaccharide Expression," Infect. Immun. 62: 3984-3993 | |
| | | PICKETT, et al. (2000) "In Vivo Characterization of the Murine Intranasal Model for Assessing the Immunogenicity of Attenuated Salmonella enterica Serovar Typhi Strains as Live Mucosal Vaccines and as Live Vectors," Infect. Immun. 68: 205-213 | |
| | | PIE, et al. (1997) "Th1 Response in Salmonella typhimurium-Infected Mice with a High or Low Rate of Bacterial Clearance," Infect. Immun. 65: 4509-4514 | |
| | | PIER, et al. (1998) "Salmonella typhi uses CFTR to enter intestinal epithelial cells," Nature 393: 79-82 | |
| | | POIRER, et al. (1988) "Protective Immunity Evoked by Oral Administration of Attenuated araA Salmonella typhimurium Expressing Cloned Streptococcal M Protein," J. Exp. Med. 168: 25-32 | |
| | | PULKKINEN and MILLER (1991) "A Salmonella typhimurium Virulence Protein Is Similar to a Yersinia enterocolitica Invasion Protein and a Bacteriophage Lambda Outer Membrane Protein," J. Bacteriol. 173: 86-93 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|--|----------------|
| | | QIAN and PAN (2002) "Construction of a tetR-Integrated Salmonella enterica Serovar Typhi CVD908 Strain That Tightly Controls Expression of the Major Merozoite Surface Protein of Plasmodium falciparum for Applications in Human Vaccine Production," Infect. Immun. 70: 2029-2038 | |
| | | RAKEMAN, et al. (1999) "A HilA-Independent Pathway to Salmonella typhimurium Invasion Gene Transcription," J. Bacteriol. 181: 3096-3104 | |
| | | RICHTER-DAHLFORS, et al. (1997) "Murine Salmonellosis Studied by Confocal Microscopy: Salmonella typhimurium Resides Intracellularly Inside Macrophages and Exerts a Cytotoxic Effect on Phagocytes In Vivo," J. Exp. Med. 186: 569-580 | |
| | | ROBBE-SAULE, et al. (1995) "The live oral typhoid vaccine Ty21a is a rpoS mutant and is susceptible to various environmental stresses," FEMS Microbiol. Lett. 126: 171-176 | |
| | | ROBERTS, et al. (2000) "Comparison of Abilities of Salmonella enterica Serovar Typhimurium aroA aroD and aroA htrA Mutants To Act as Live Vectors," Infect. Immun. 68: 6041-6043 | |
| | | ROBERTS, et al. (1999) "Prior Immunity to Homologous and Heterologous Salmonella Serotypes Suppresses Local and Systemic Anti-Fragment C Antibody Responses and Protection from Tetanus Toxin in Mice Immunized with Salmonella Strains Expressing Fragment C," Infect. Immun. 67: 3810-3815 | |
| | | ROBERTS, et al. (1998) "Oral Vaccination against Tetanus: Comparison of the Immunogenicities of Salmonella Strains Expressing Fragment C from the nirB and htrA Promoters," Infect. Immun. 66: 3080-3087 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | ROLAND, et al. (1999) "Construction and Evaluation of a Δcya Δcrp Salmonella typhimurium Strain Expressing Avian Pathogenic Escherichia coli O78 LPS as a Vaccine to Prevent Airsacculitis in Chickens," Avian Diseases 43: 429-441 | |
| | | SCHÖDEL, et al. (1993) "Avirulent Salmonella expressing hybrid hepatitis B virus core/pre-S genes for oral vaccination," Vaccine 11: 143-148 | |
| | | SCHÖDEL, et al. (1994) "Development of Recombinant Salmonellae Expressing Hybrid Hepatitis B Virus Core Particles as Candidate Oral Vaccines," Brown F(ed): Recombinant Vectors in Vaccine Development. Dev. Biol. Stand. Basel, Karger 82: 151-158 | |
| | | SCHWAN, et al. (2000) "Differential Bacterial Survival, Replication, and Apoptosis-Inducing Ability of Salmonella Serovars within Human and Murine Macrophages," Infect. Immun. 68: 1005-1013 | |
| | | SHATA, et al. (2000) "Recent advances with recombinant bacterial vaccine vectors," Mol. Med. Today 6: 66-70 | |
| | | SINHA, et al. (1997) "Salmonella typhimurium aroA, htrA, and aroD htrA Mutants Cause Progressive Infections in Athymic (nu/nu) BALB/c Mice," Infect. Immun. 65: 1566-1569 | |
| | | SIRARD, et al. (1999) "Live attenuated Salmonella: a paradigm of mucosal vaccines," Immunol. Rev. 171: 5-26 | |
| | | SMITH, et al. (1984) "Aromatic-dependent Salmonella dublin as a parenteral modified live vaccine for calves," Am. J. Vet. Res. 45: 2231-2235 | |
| | | SMITH, et al. (1993) "Vaccination of calves with orally administered aromatic-dependent Salmonella dublin," Am. J. Vet. Res. 54: 1249-1255 | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**INFORMATION DISCLOSURE
STATEMENT LIST**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|--|----------------|
| | | SOO, et al. (1998) "Genetic Control of Immune Response to Recombinant Antigens Carried by an Attenuated Salmonella typhimurium Vaccine Strain: Nramp1 Influences T-Helper Subset Responses and Protection against Leishmanial Challenge," Infect. Immun. 66: 1910-1917 | |
| | | SPRENG, et al. (200) "Salmonella vaccines secreting measles virus epitopes induce protective immune responses against measles virus encephalitis," Microbes Infect. 2: 1687-1692 | |
| | | STEIN, et al. (1996) "Identification of a Salmonella virulence gene required for formation of filamentous structures containing lysosomal membrane glycoproteins within epithelial cells," Mol. Microbiol. 20: 151-164 | |
| | | STOCKER (2000) "Aromatic-dependent Salmonella as anti-bacterial vaccines and as presenters of heterologous antigens or of DNA encoding them," J. Biotechnol. 83: 45-50 | |
| | | STOCKER (1990) "Aromatic-Dependent Salmonella as Live Vaccine Presenters of Foreign Epitopes as Inserts in Flagellin," Res. Microbiol. 141: 787-796 | |
| | | STOCKER (1988) "Auxotrophic Salmonella typhi as live vaccine," Vaccine 6: 141-145 | |
| | | SVENSON and LINDBERG (1983) "Artificial Salmonella Vaccines," Prog. Allergy 33: 120-143 | |
| | | SYDENHAM, et al. (2000) "Salmonella enterica Serovar Typhimurium surA Mutants Are Attenuated and Effective Live Oral Vaccines," Infect. Immun. 68: 1109-1115 | |
| | | SZTEIN, et al. (1994) "Cytokine Production Patterns and Lymphoproliferative Responses in Volunteers Orally Immunized with Attenuated Vaccine Strains of Salmonella typhi," J. Infect. Disease 170: 1508-1517 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office; P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | TACKET, et al. (2000) "Phase 2 Clinical Trial of Attenuated Salmonella enterica Serovar Typhi Oral Live Vector Vaccine CVD 908-htrA in U.S. Volunteers," Infect. Immun. 68: 1196-1201 | |
| | | TACKET, et al. (2000) "Safety and Immune Responses to Attenuated Salmonella enterica Serovar Typhi Oral Live Vector Vaccines Expressing Tetanus Toxin Fragment C," Clin. Immunol. 97: 146-153 | |
| | | TACKET, et al. (1997) "Safety of Live Oral Salmonella typhi Vaccine Strains with Deletions in htrA and aroC aroD and Immune Response in Humans," Infect. Immun. 65: 452-456 | |
| | | TACKET, et al. (1992) "Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain," Vaccine 10: 443-446 | |
| | | TACKET, et al. (1992) "Comparison of the Safety and Immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella typhi Strains in Adult Volunteers," Infect. Immun. 60: 536-541 | |
| | | TACKET, et al. (1991) "Lack of Immune response to the Vi Component of a Vi-Positive Variant of Salmonella typhi Live Oral Vaccine Strain Ty21a in Human Studies," J. Infect. Disease 163: 901-904 | |
| | | TACKET, et al. (1988) "Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever," Vaccine 6: 307-308 | |
| | | TACKET, et al. (1986) "Safety and Immunogenicity of Two Salmonella typhi Vi Capsular Polysaccharide Vaccines," J. Infect. Disease 154: 342-345 | |
| | | TAGLIABUE (1989) "Immune Response to Oral Salmonella Vaccines," Curr. Topics Microbiol. Immunol. 146: 225-231 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | TANG, et al. (2001) "Identification of bacterial genes required for in-vivo survival," J. Pharm. Pharmacol. 53: 1575-1579 | |
| | | TITE, et al. (1991) "The Involvement of Tumor Necrosis Factor in Immunity to Salmonella Infection," J. Immunol. 147: 3161-3164 | |
| | | TRAMONT, et al. (1984) "Safety and Antigenicity of Typhoid-Shigella sonnei Vaccine (Strain 5076-1C)," J. Infect. Disease 149: 133-136 | |
| | | TURNER, et al. (1993) "Salmonella typhimurium ΔaroA ΔaroD Mutants Expressing a Foreign Recombinant Protein Induce Specific Major Histocompatibility Complex Class I-Restricted Cytotoxic T Lymphocytes in Mice," Infect. Immun. 61: 5374-5380 | |
| | | UCHIYA, et al. (1999) "A Salmonella virulence protein that inhibits cellular trafficking," EMBO J. 18: 3924-3933 | |
| | | URASHIMA, et al. (2000) "An oral CD40 ligand gene therapy against lymphoma using attenuated Salmonella typhimurium," Blood 95: 1258-1263 | |
| | | VALDIVIA and FALKOW (1996) "Bacterial genetics by flow cytometry: rapid isolation of Salmonella typhimurium acid-inducible promoters by differential fluorescence induction," Mol. Microbiol. 22: 367-378 | |
| | | VAN DISSEL, et al. (1995) "S. Typhi Vaccine Strain Ty21a Can Cause a Generalized Infection in Whole Body-Irradiated But Not in Hydrocortisone-Treated Mice," Scand. J. Immunol. 41: 457-461 | |
| | | VAN VELKINBURGH and GUNN (1999) "PhoP-PhoQ-Regulated Loci Are Required for Enhanced Bile Resistance in Salmonella spp.," Infect. Immun. 67: 1614-1622 | |

| | |
|--|-----------------|
| Examiner Signature: | Date Considered |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | VANCOTT, et al. (1998) "Regulation of host immune responses by modification of Salmonella virulence genes," Nat. Med. 4: 1247-1252 | |
| | | VANCOTT, et al. (1996) "Regulation of Mucosal and Systemic Antibody Responses by T Helper Cell Subsets, Macrophages, and Derived Cytokines Following Oral Immunization with Live Recombinant Salmonella," J. Immunol. 1504: 1514 | |
| | | VAZQUEZ-TORRES, et al. (2000) "Salmonella Pathogenicity Island 2-Dependent Evasion of the Phagocyte NADPH Oxidase," Science 287: 1655-1658 | |
| | | VÉSCOVI, et al. (1996) "MG2+ as an Extracellular Signal: Environmental Regulation of Salmonella Virulence," Cell 84: 165-174 | |
| | | VILLARREAL, et al. (1992) "Proliferative and T-cell specific interleukin (IL-2/IL-4) production responses in spleen cells from mice vaccinated with aroA live attenuated Salmonella vaccines," Microbial Pathogen. 13: 305-315 | |
| | | VIRET, et al. (1999) "Mucosal and Systemic Immune Responses in Humans after Primary and Booster Immunizations with Orally Administered Invasive and Noninvasive Live Attenuated Bacteria," Infect. Immun. 67: 3680-3685 | |
| | | VIRLOGEUX, et al. (1996) "Characterization of the rcsA and rcsB Genes from Salmonella typhi: rcsB through tvia Is Involved in Regulation of Vi Antigen Synthesis," J. Bacteriol. 178: 1691-1698 | |
| | | VIRLOGEUX, et al. (1995) "Role of the viaB locus in synthesis, transport and expression of Salmonella typhi Vi antigen," Microbiol. 141: 3039-3047 | |
| | | WAHDAN, et al. (1982) "A Controlled Field Trial of Live Salmonella typhi Strain Ty 21a Oral Vaccine Against Typhoid: Three-Year Results," J. Infect. Dis. 145: 292-295 | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | WAHDAN, et al. (1980) "A controlled field trial of live oral typhoid vaccine Ty21a," Bull. World Health Org. 58: 469-474 | |
| | | WALLIS (2001) "Salmonella Pathogenesis and Immunity: We Need Effective Multivalent Vaccines," Vet. J. 161: 104-106 | |
| | | WALLIS and GALYOV (2000) "Molecular basis of Salmonella-induced enteritis," Mol. Microbiol. 36: 997-1005 | |
| | | WANG, et al. (2000) "Constitutive Expression of the Vi Polysaccharide Capsular Antigen in Attenuated Salmonella enterica Serovar Typhi Oral Vaccine Strain CVD 909," Infect. Immun. 68: 4647-4652 | |
| | | WARD, et al. (1999) "Immunogenicity of a Salmonella typhimurium aroA aroD Vaccine Expressing a Nontoxic Domain of Clostridium difficile Toxin A," Infect. Immun. 67: 2145-2152 | |
| | | WEDEMEYER, et al. (2001) "Oral Immunization With HCV-NS3-Transformed Salmonella: Induction of HCV-Specific CTL in a Transgenic Mouse Model," Gastroenterology 121: 1158-1166 | |
| | | WEINSTEIN, et al. (1998) "Differential Early Interactions between Salmonella enterica Serovar Typhi and Two Other Pathogenic Salmonella Serovars with Intestinal Epithelial Cells," Infect. Immun. 66: 2310-2318 | |
| | | WEINSTEIN, et al. (1997) "Salmonella typhi Stimulation of Human Intestinal Epithelial Cells Induces Secretion of Epithelial Cell-Derived Interleukin-6," Infect. Immun. 65: 395-404 | |
| | | WEINTRAUB, et al. (1997) "Role of $\alpha\beta$ and $\gamma\delta$ T Cells in the Host Response to Salmonella Infection as DEMonstrated in T-Cell-Receptor-Deficient Mice of Defined Ity Genotypes," Infect. Immun. 65: 2306-2312 | |

Examiner Signature:

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|---------------------|-----------------------|---|----------------|
| | | WHITE, et al. (1999) "High efficiency gene replacement in Salmonella enteritidis chimeric fimbrins containing a T-cell epitope from Leishmania major," Vaccine 17: 2150-2161 | |
| | | WONG, et al. (1974) "Vi Antigen from Salmonella typhosa and Immunity Against Typhoid Fever," Infect. Immun. 9: 348-353 | |
| | | WOO, et al. (2001) "Unique immunogenicity of hepatitis B virus DNA vaccine presented by live attenuated Salmonella typhimurium," Vaccine 19: 2945-2954 | |
| | | WU, et al. (2000) "Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium falciparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C," J. Biotechnol. 83: 125-135 | |
| | | WÜTHRICH, et al. (1985) "Typhusepidemiologie in der Schweiz 1980-1983," Schweiz. med. Wschr. 115: 1714-1720 | |
| | | WYANT, et al. (1999) "Salmonella typhi Flagella Are Potent Inducers of Proinflammatory Cytokine Secretion by Human Monocytes," Infect. Immun. 67: 3619-3624 | |
| | | ZHANG, et al. (1999) "Protection and immune responses induced by attenuated Salmonella typhimurium UK-1 strains," Microbial Pathogen. 26: 121-130 | |
| | | ZHOU, et al. (1999) "An invasion-associated Salmonella protein modulates the actin-bundling activity of plactin," Proc. Natl. Acad. Sci. USA 96: 10176-10181 | |
| | | CURTISS, et al. (1994) "Recombinant <i>Salmonella</i> vectors in vaccine development" Dev. Biol. Stand. 82:23-33 | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/763,883 |
| Filing Date | January 23, 2004 |
| First Named Inventor | Michael HENSEL |
| Art Unit | 1645 |
| Examiner Name | Khatol S. Shahnan |
| Attorney Docket Number | EMER-003/02US |

NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|------------------------|--------------------------|--|----------------|
| | | GALEN et al. (1997) "A murine model of intranasal immunization to assess the immunogenicity of attenuated <i>Salmonella typhi</i> live vector vaccines in stimulating serum antibody responses to expressed foreign antigens," Vaccine, 15:700-708 | |
| | | HORMAECHE, (1979) "Genetics of natural resistance to salmonellae in mice," Immunology, 37:319-327 | |
| | | JONES, et al. (1991) "Oral vaccination of calves against experimental salmonellosis using a double <i>aro</i> mutant of <i>Salmonella typhimurium</i> ," Vaccine, 9:29-34 | |
| | | JONES-CARSON et al. (2007) "Systemic CD8 T cell memory response to a <i>Salmonella</i> pathogenicity island 2 effector is restricted to <i>Salmonella enterica</i> encountered in the gastrointestinal mucosa," Infect. Immun. 75:2708-2716 | |
| | | CHENOWETH et al. (1990) "Efficacy of ampicillin versus trimethoprim-sulfamethoxazole in a mouse model of lethal enterococcal peritonitis," Antimicrob. Agents Chemother. 34:1800-1802 | |
| | | KOHLER, et al. (1998) "Oral immunization with recombinant <i>Salmonella typhimurium</i> expressing a cloned porphyromonas gingivalis hemagglutinin: effect of bovine on mucosal systemic and immunoglobulin G subclass response," Oral Microbiol. Immunol. 13:81-88. ABSTRACT ONLY | |
| | | O'CALLAGHAN, et al. (1990) "Immunogenicity of foreign peptide epitopes expressed in bacterial envelope proteins," Res. Microbiol. 141:963-969 ABSTRACT ONLY | |
| | | SCHODEL, et al. (1996) "Hybrid hepatitis B virus core antigen as a vaccine carrier moiety II. Expression in avirulent <i>Salmonella</i> spp. for mucosal immunization," Adv. Exp. Med. Biol. 397:15-21. ABSTRACT ONLY | |

| | | | |
|--|--|-----------------|--|
| Examiner Signature: | | Date Considered | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.